Gilead OKs Generic Sovaldi To Expand Global Access

By | September 15, 2014

Scalper1 News

Big-cap biotech and IBD 50 stock Gilead Sciences (GILD) said Monday that it’s licensing its megablockbuster hepatitis C drug Sovaldi to seven Indian generic-drug companies to improve access in 91 developing countries. Gilead’s stock fell about 2% on the stock market today. The Sovaldi licensing deal includes the big names in the Indian drug business, such as Ranbaxy Labs and Cipla, as well as U.S.-based Mylan (MYL). The drugmakers will be able to Scalper1 News

Scalper1 News